Letter to the EditorPeripubertal treatment with cannabidiol prevents the emergence of psychosis in an animal model of schizophrenia
Section snippets
Contributors
Fernanda F. Peres, Rodrigo A. Bressan, Antonio W. Zuardi, Jaime E. C. Hallak, José A. Crippa and Vanessa C. Abilio designed the study. Authors Fernanda F. Peres, Mariana C. Diana, Mayra A. Suiama, Verônica Justi and Valéria Almeida conducted the experiments, statistical analysis and managed the literature search. Authors Fernanda F. Peres and Vanessa C. Abilio wrote the first draft of the manuscript. All authors contributed to and have approved the final manuscript.
Conflict of interest
J.E.H., A.W.Z. and J.A.C. are co-inventors of the patent “Fluorinated CBD compounds, compositions and uses thereof. Pub. No.: WO/2014/108899. International Application No.: PCT/IL2014/050023”.
References (8)
- et al.
Cannabidiol exhibits anxiolytic but not antipsychotic property evaluated in the social interaction test
Prog. Neuro-Psychopharmacol. Biol. Psychiatry
(2013) - et al.
Effects of antipsychotics and amphetamine on social behaviors in spontaneously hypertensive rats
Behav. Brain Res.
(2011) - et al.
A review of 25 years of the social interaction test
Eur. J. Pharmacol.
(2003) - et al.
To model a psychiatric disorder in animals: schizophrenia as a reality test
Neuropsychopharmacology
(2000)
There are more references available in the full text version of this article.
Cited by (0)
Copyright © 2016 Elsevier B.V. All rights reserved.